Revvity (NYSE:RVTY) FY Conference Summary Company Overview - Revvity has undergone significant transformation over the past decade, evolving from a company with equal focus on analytical, life sciences, and diagnostics to a balanced portfolio of approximately $3 billion, split evenly between life sciences and diagnostics [2][4] - The life sciences business has expanded into large molecule capabilities, while diagnostics has diversified beyond reproductive health into autoimmune, allergy, and emerging diseases [3] Financial Performance - Revvity's revenue is approximately $3 billion, with 85% of the portfolio being recurring revenue [4] - The life sciences segment generates about $1.5 billion, with 85% from innovative reagents and instrumentation, and 15% from software [5] - The diagnostics segment also contributes around $1.5 billion, with 60% from immunodiagnostics and 40% from reproductive health [6] Growth Drivers - Revvity identifies four key growth pillars: 1. **Software Business**: Launching new products like Xynthetica, BioDesign, and Signals LabGistics, which are expected to enhance drug discovery and lab management [8][9][10] 2. **Immunodiagnostics**: Targeting a market share increase from 20% to 40% in the U.S. [11] 3. **GMP Innovation**: Building capabilities in Good Manufacturing Practices, with expectations for significant growth in the coming years [11][41] 4. **Strategic Partnerships**: Collaborations with companies like Sanofi and Genomics England to enhance service offerings [10] Market Outlook - Revvity anticipates organic growth of 2%-3% for 2026, with expectations of low single-digit growth in life sciences solutions and mid-single-digit growth in reproductive health [30][35] - The company does not expect a market recovery in pharma and biotech for 2026, but sees potential for growth in other areas [33] Operational Excellence - Revvity has improved free cash flow conversion to approximately 90% from a historical 70% [12] - The company plans for a 100 basis point margin expansion in 2026, with further expansion expected in 2027 due to cost benefits [13][68] AI and Drug Development - Revvity views AI as a net tailwind for both its reagents and software businesses, facilitating drug discovery and creating a validation bottleneck that will increase demand for wet lab services [20][26] - The company is positioned to leverage AI through its software offerings, creating a marketplace for AI models that integrates with existing lab research [21][25] Competitive Landscape - Revvity maintains a competitive advantage through best-in-class customer service, rapid delivery of reagents, and a strong innovation pipeline [44][45] - The company is monitoring competitive disruptions from industry transactions, such as the Waters BD transaction, but believes its moat remains strong [44] Challenges and Risks - The company has adopted a more prudent approach to growth assumptions in the Chinese market due to regulatory changes [58] - Potential tariff impacts on diagnostics manufacturing in Europe are being monitored, with plans to mitigate exposure [63] Conclusion - Revvity is optimistic about its growth trajectory, driven by innovation, strategic partnerships, and operational improvements, while navigating challenges in the pharma and biotech markets [16][70]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated revenue of $772 million, resulting in 4% organic growth, with a full-year revenue of $2.86 billion, reflecting 3% organic growth [22][24] - Adjusted EPS for Q4 was $1.70, exceeding the high end of expectations, while full-year adjusted EPS was $5.06, representing 3% growth year-over-year [10][24] - Adjusted operating margins for Q4 were 29.7%, down 60 basis points year-over-year, and for the full year, they were 27.1%, down 120 basis points year-over-year [23][24] Business Line Data and Key Metrics Changes - The diagnostics segment saw revenue of $390 million in Q4, up 10% reported and 7% organic, while the life sciences segment generated $382 million, flat on an organic basis [26][28] - For the full year, diagnostics grew 4% organically, while life sciences grew 2% organically [26][27] - The Signals software business was flat year-over-year organically in Q4 but grew in the high teens organically for the full year [27] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, with double-digit growth in Europe [26] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [26] Company Strategy and Development Direction - The company plans to continue capital deployment through share repurchases and acquisitions, having repurchased over $800 million worth of shares in 2025 [10][11] - The acquisition of ACD/Labs is expected to contribute over $20 million in revenue in 2026, adding approximately 75 basis points to overall revenue growth [12][13] - The introduction of the AI models-as-a-service platform, Signals Xynthetica, is aimed at enhancing drug development processes [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, reiterating a 2%-3% organic growth outlook for 2026 [12][31] - The company noted potential upside from improved customer sentiment in pharma and biotech, as well as ongoing cost efficiency initiatives [20][22] - Management highlighted the importance of maintaining a disciplined approach to capital deployment while navigating a fluid market environment [11][20] Other Important Information - The company generated free cash flow of $162 million in Q4, resulting in 84% conversion of adjusted net income, with a full-year free cash flow of $515 million [25] - The net debt to adjusted EBITDA leverage ratio was 2.7x, with 100% of debt being fixed rate [25] Q&A Session Summary Question: Can you provide more color on the 2%-3% organic growth framework and potential upside? - Management acknowledged positive signs in end markets since September and identified multiple paths for potential upside in both revenue and EPS [39][40] Question: What is the outlook for life sciences versus diagnostics relative to the 2%-3% growth? - Management indicated that life sciences is expected to grow at low single digits, while diagnostics is also expected to grow at low single digits, with specific growth rates for sub-segments [55] Question: How is the company approaching M&A opportunities? - Management stated that any potential M&A must provide a strong strategic addition and that they have not yet identified compelling targets [58] Question: Can you elaborate on the performance within pharma biotech and order trends? - Management noted cautious optimism and consistency in order trends, with no budget flush observed but improved clarity in the policy environment [60][61] Question: What are the expectations for the diagnostics business going into 2026? - Management expressed that diagnostics could provide upside, particularly in newborn screening and immunodiagnostics, despite taking a more prudent approach to assumptions [63][64]

Financial Data and Key Metrics Changes - The company experienced an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors including the Genomics England contract which contributed around $7 million in Q4 compared to $2 million in Q3 [1][2] - The foreign exchange (FX) impact was a drag of $5-$7 million, which is 1% less than previously predicted, affecting absolute dollar amounts but having minimal impact on growth and earnings per share (EPS) [3] Business Line Data and Key Metrics Changes - The life sciences instrumentation side has shown good activity, with seasonal uplift expected rather than a significant budget flush [2][12] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, but the pharma biotech sector has shown signs of recovery [5][8] - The software segment has grown over 20% each quarter, significantly exceeding guidance, driven by diligent investment and customer engagement [19][21] Market Data and Key Metrics Changes - The U.S. market for EUROIMMUN has increased from 5% to 15-20% of total revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [36] - The China diagnostics market is projected to stabilize, with expectations of it contributing 5-6% to total revenue, while autoimmune testing is anticipated to grow significantly [43][44] Company Strategy and Development Direction - The company is focusing on leveraging AI and machine learning in drug discovery and development, positioning itself as a critical player in the future of pharmaceutical research [22][31] - Strategic acquisitions will continue, with a focus on sensible and financially sound opportunities, as demonstrated by the recent acquisition of ACD/Labs [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased discussions and activity are signs of normalization [15][16] - The company is confident in its 2026 growth projections of 2-3% and 28% margins, accounting for stable market conditions and the impact of calendarization on China [54][56] Other Important Information - The company has been actively integrating AI across its product lines and internal operations, enhancing productivity and efficiency [34][35] - The newborn screening market has shown growth due to geographic expansion and the introduction of new assays, with partnerships driving further opportunities [46][48] Q&A Session Summary Question: Can you discuss the impact of the government shutdown on the reagents business? - The reagents business, particularly from BioLegend, experienced a modest impact from the shutdown, but the pharma biotech sector has continued to perform well [5][8] Question: What are the expectations for the software business moving into 2026? - The software business is expected to continue performing well, with a focus on annualized portfolio value (APV) rather than just organic growth [27][28] Question: How does the company view the China diagnostics market going forward? - The company anticipates that the China diagnostics market will stabilize, contributing around 5-6% to total revenue, with a focus on localizing operations and obtaining faster approvals [43][44]